| 邱恩铎 张晓晶 商冠宁 王玉名 郑珂.人参皂苷对骨肉瘤患者血清VEGF及TSGF水平的影响及临床疗效[J].,2016,16(6):1067-1069 |
| 人参皂苷对骨肉瘤患者血清VEGF及TSGF水平的影响及临床疗效 |
| Effect of Ginsenoside on the SerumVEGF and TSGF Levels and ClinicalEfficacy of Patients with Osteosarcoma |
| |
| DOI： |
| 中文关键词: 人参皂苷 骨肉瘤 血清血管内皮生长因子 肿瘤特异性生长因子 临床疗效 |
| 英文关键词: Ginsenoside Osteosarcoma VEGF TSGF Clinical efficacy |
| 基金项目:辽宁省教育厅科技研究项目(2008557) |
|
| 摘要点击次数: 1068 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探讨人参皂苷对骨肉瘤患者血清血管内皮生长因子(VEGF)、肿瘤特异性生长因子(TSGF)的影响及临床疗效。方法：收
集我院收治的骨肉瘤患者60 例，根据用药不同分为对照组和实验组，每组30 例。对照组采用FOLFOX4 方案化疗，实验组在对照
组基础上加用人参皂苷治疗。观察并比较两组患者治疗前后的肿瘤体积、血清VEGF及TSGF水平变化以及临床疗效。结果：与治
疗前比较，两组患者治疗后的肿瘤体积均显著减小，血清VEGF 及TSGF水平均显著下降，差异具有统计学意义(P<0.05)；与对照
组相比，实验组患者治疗后肿瘤体积减小更明显，血清VEGF及TSGF水平下降更显著，差异具有统计学意义(P<0.05)；实验组患
者治疗总有效率(80.0%)显著高于对照组(46.67%)，差异具有统计学意义(P=0.009)。结论：人参皂苷能够显著降低骨肉瘤患者血清
VEGF及TSGF水平，减小肿瘤体积，临床疗效显著。 |
| 英文摘要: |
| Objective:To investigate the effect of Ginsenoside on the serum VEGF, TSGF levels and clinical efficacy of patients
with osteosarcoma.Methods:60 patients with osteosarcoma who were treated in our hospital were selected and divided into two groups
according to different treatment, with 30 cases in each group. The patients in the control group were treated with FOLFOX4 regime,
while the patients in the experimental group were treated with FOLFOX4 regime combined with ginsenoside. Then the tumor volume,
serum levels of VEGF and TSGF and efficacy in the two groups were observed and compared before and after the treatment.Results:Compared with the treatment, the tumor volume, the serum levels of VEGF and TSGF significantly decreased, and the difference was
statistically significant (P<0.05); compared with the control group, the serum levels of VEGF and TSGF decreased significantly, and the
difference was statistically significant (P<0.05); the total effective rate in the experimental group (80.0%) was significantly higher than
that of the control group (46.67%), and the difference was statistically significant (P=0.009).Conclusion:Ginsenoside could significantly
reduce the serumlevels of VEGF and TSGF and tumor volume of patients with osteosarcoma, which could promote the clinical efficacy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
